Evidence map›Paper›PMID 28471483›Full record

ArticleArthritis & rheumatology (Hoboken, N.J.)2017

Bone Marrow-Derived Mesenchymal Stem Cells From Patients With Systemic Lupus Erythematosus Have a Senescence-Associated Secretory Phenotype Mediated by a Mitochondrial Antiviral Signaling Protein-Interferon-β Feedback Loop.

Lin Gao, Anna K Bird, Nida Meednu, Kristin Dauenhauer, Jane Liesveld, Jennifer Anolik, R John Looney

Open access · greenAbstract read
In one paragraph

Article in Arthritis & rheumatology (Hoboken, N.J.), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed
5.3field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 75 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Lin GaoUniversity of Rochester Medical Center, Rochester, New York.
Anna K BirdUniversity of Rochester Medical Center, Rochester, New York.
Nida MeednuUniversity of Rochester Medical Center, Rochester, New York.
Kristin DauenhauerUniversity of Rochester Medical Center, Rochester, New York.
Jane LiesveldUniversity of Rochester Medical Center, Rochester, New York.
Jennifer AnolikUniversity of Rochester Medical Center, Rochester, New York.
R John LooneyUniversity of Rochester Medical Center, Rochester, New York.
University of Rochester Medical Center · US

Funding

The University of Rochester's Clinical and Translational Science InstituteUL1TR000042 · NCATS · UNIVERSITY OF ROCHESTER · PI BENNETT, NANCY M, KIEBURTZ, KARL D. · 2012 to 2015
$14.4M
Cellular Dynamics at the Synovium-Bone interface in RAUH2AR067690 · NIAMS · UNIVERSITY OF ROCHESTER · PI ANOLIK, JENNIFER HOWITT · 2014 to 2020
$3.0M
B-Cell Tolerance Mechanisms in Human SLER01AI077674 · NIAID · UNIVERSITY OF ROCHESTER · PI ANOLIK, JENNIFER HOWITT · 2009 to 2013
$2.0M
NCATS NIH HHS UL1 TR000042NIAID NIH HHS R01 AI077674NIAMS NIH HHS UH2 AR067690
6 · The paper itself

Abstract

objectiveBone marrow-derived mesenchymal stem cells (BM-MSCs) create a special microenvironment for hematopoiesis and immunity and display robust immunomodulatory properties that are impaired in systemic lupus erythematosus (SLE). This study was undertaken to identify the mechanisms of defects in human SLE BM-MSCs.

methodsPatients fulfilling SLE classification criteria and healthy controls (n = 6 per group) were recruited according to an institutional review board-approved protocol. BM-MSCs were isolated with low-density Ficoll-Hypaque, verified by flow cytometry, and studied using immunocytochemistry, real-time polymerase chain reaction, Western blotting, comet assay, β-galactosidase assay, and RNA interference.

resultsSLE BM-MSCs had a senescent phenotype characterized by a reduced proliferation rate, increased production of reactive oxygen species, increased DNA damage and repair, increased expression of p53 and p16, which block the cell cycle, and altered cytokine production (increased proinflammatory cytokine production and decreased immunomodulatory cytokine production). Moreover, SLE BM-MSCs had a 5-fold increase in interferon-β (IFNβ) levels (P < 0.05 versus healthy controls) and increased IFNβ-induced messenger RNAs (mRNAs), including mRNA for the intracellular nucleic acid-sensing adaptor protein mitochondrial antiviral signaling protein (MAVS), whose expression was highly correlated with IFNβ levels (r > 0.9, P < 0.01). Since MAVS is known to induce IFNβ production, we hypothesized that there is a positive feedback loop between MAVS and IFNβ. Notably, silencing of MAVS markedly decreased IFNβ, p53, and p16 protein levels and expression of mRNAs for proinflammatory cytokines.

conclusionThis study demonstrates a novel pathway for elevated IFNβ signaling in SLE that is not dependent on stimulation by immune complexes but rather is cell intrinsic and critically mediated by IFNβ and MAVS, implicating new pathways as potential therapeutic targets.

Indexed as

Adaptor Proteins, Signal TransducingAdultBlotting, WesternBone MarrowCellular SenescenceCyclin-Dependent Kinase Inhibitor p16CytokinesFeedbackFemaleFlow CytometryHumansInterferon-betaLupus Erythematosus, SystemicMesenchymal Stem CellsMiddle AgedPhenotypeAdaptor Proteins, Signal TransducingCDKN2A protein, humanCyclin-Dependent Kinase Inhibitor p16CytokinesInterferon-betaMAVS protein, humanRNA, MessengerTP53 protein, humanTumor Suppressor Protein p53

Identifiers

PMID28471483
PMCPMC5560120
OpenAlexW2898054633

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.